Lecozotan

Lecozotan is an investigational drug by Wyeth tested for improvement of cognitive functions of Alzheimer's disease patients.^[1] As of June 2008^[update], the first Phase III clinical trial has been completed.^[2]

Lecozotan

Identifiers
IUPAC name 4-Cyano-N-[(2R)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]propyl]-N-2-pyridinylbenzamide hydrochloride
CAS Number	434283-16-6
PubChem CID	10116877
ChemSpider	8292400
UNII	48854OTZ5E
KEGG	D04683 Y
ChEMBL	ChEMBL372205
CompTox Dashboard (EPA)	DTXSID20195826
Chemical and physical data
Formula	C28H30ClN5O3
Molar mass	520.03 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H](CN(C1=CC=CC=N1)C(=O)C2=CC=C(C=C2)C#N)N3CCN(CC3)C4=C5C(=CC=C4)OCCO5
InChI InChI=1S/C28H29N5O3/c1-21(31-13-15-32(16-14-31)24-5-4-6-25-27(24)36-18-17-35-25)20-33(26-7-2-3-12-30-26)28(34)23-10-8-22(19-29)9-11-23/h2-12,21H,13-18,20H2,1H3/t21-/m1/s1 Key:NRPQELCNMADTOZ-OAQYLSRUSA-N
(verify)

Method of action

Lecozotan is a competitive, selective 5-HT_1A receptor antagonist^[3] which enhances the potassium-stimulated release of acetylcholine and glutamate.^[4]